A phase 2b study of OKG-0303 for the treatment of acute infectious conjunctivitis
Latest Information Update: 26 Dec 2024
At a glance
- Drugs OKG-0303 (Primary)
- Indications Infectious conjunctivitis
- Focus Therapeutic Use
- 11 Dec 2024 According to an Okogen, Inc. media release, the company expects a Phase 2b data readout by Q4 2025.
- 03 Nov 2023 New trial record
- 31 Oct 2023 According to an Okogen, Inc. media release, company announced initiation of this trial.